interferon alfa 2a

DRUG3 trials

Sponsors

Third Affiliated Hospital, Sun Yat-Sen University, Leiden University Medical Center, Novartis

Conditions

Chronic Hepatitis bEfficacy, SelfOvarian Cancer Recurrentrenal cell cancer

Phase 1

Adoptive T Cell Therapy in Patients With Recurrent Ovarian Cancer

Leiden University Medical CenterOvarian Cancer Recurrent

Start: 2018-08-01End: 2021-12-01Target: 12Updated: 2021-04-01

Phase 2

A randomized, open label, multi-center phase II study to compare bevacizumab plus RAD001 versus interferon alfa-2a and bevacizumab for the first-line treatment of patients with metastatic clear cell carcinoma of the kidney

Active, not recruitingNL-OMON34911

Novartisrenal cell cancer

Start: 2009-09-16Target: 6Updated: 2024-02-28

Unknown Phase

Optimal Treatment for Poor Efficacy of Entecavir in Chronic Hepatitis B Patients

Third Affiliated Hospital, Sun Yat-Sen UniversityChronic Hepatitis b, Efficacy, Self

Start: 2018-11-15End: 2021-12-31Target: 100Updated: 2018-11-23

Related Papers

Timed adoptive T cell transfer during chemotherapy in patients with recurrent platinum-sensitive epithelial ovarian cancer

Journal for ImmunoTherapy of Cancer2023-11-0124 citations

PO008/#393 Timed adoptive T-cell therapy during chemotherapy in platinum sensitive recurrent epithelial ovarian cancer, the ovacure phase I/II trial

2023-11-01

356 Personalized immunotherapy by adoptive T cell transfer during chemotherapy with or without interferon-alpha in patients with recurrent platinum-sensitive epithelial ovarian cancer

Regular and Young Investigator Award Abstracts2021-11-01